Tevogen Bio Holdings Inc.
$0.25
-5.8%Tevogen Bio Holdings Inc. operates as a clinical-stage biotechnology company that develops off-the-shelf precision T cell therapeutics in virology, oncology, and neurology. Its lead investigational precision T cell product, TVGN 489, is designed to address the unmet need of acute-risk COVID-19 patients, as well as a subset of patients suffering from long COVID. The company is based in Warren, New Jersey.
At a Glance
Live SnapshotIntrinsic Alpha Methodology
Thesis Lenses
Signal
Medium confidenceValuation multiple is compressed (P/E -14.9).
Valuation inputs: P/E -14.9, earnings yield N/A, momentum -5.8%.
If multiples stay elevated while momentum fades, downside repricing risk rises.
Driver
High confidenceReturn profile is soft (ROE +1.5%, ROIC +14.5%).
Profitability stack: net margin 0.0%, ROE +1.5%, ROIC +14.5%.
Quality deterioration often appears in margins before it shows up in headline EPS.
Risk
High confidenceDownside profile is elevated and scenario stress-testing is essential.
Risk factors: liabilities/assets +292.8%, momentum -5.8%, net margin 0.0%.
Higher leverage with weak momentum and thin margins can amplify drawdown severity.
Tevogen Bio Holdings Inc. Market vs Earnings Trajectory
Loading price and EPS data...
Tevogen Bio Holdings Inc. Fair Value Envelope
No Revenue Data
TVGN has not reported any revenue values in the available annual periods.
Tevogen Bio Holdings Inc. Profit Bridge
Profitability Analysis
No Gross Profit Margin Data
TVGN has not reported any gross profit margin values in the available annual periods.
No Operating Profit Margin Data
TVGN has not reported any operating profit margin values in the available annual periods.
No Net Profit Margin Data
TVGN has not reported any net profit margin values in the available annual periods.
Tevogen Bio Holdings Inc. Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Strong cash conversion. Most reported earnings translate into actual cash flow, suggesting solid fundamentals.
FCF Growth Trend
Significant FCF decline raises concerns. Urgent review needed of operational performance and capital allocation.
Working Capital Impact
Minimal working capital impact on FCF. Changes in operating assets and liabilities well-managed.
Cash Flow Quality Insight
Working capital strain: Significant cash tied up in operations. Monitor receivables collection, inventory turns, and payment terms to optimize cash conversion cycle.
Tevogen Bio Holdings Inc. Funding & Solvency Profile
Financial Health Analysis
Current Ratio
Warning: Liquidity concerns. Current assets may not be sufficient to cover short-term obligations.
Working Capital
Negative working capital indicates short-term liabilities exceed short-term assets—potential liquidity stress.
Asset Composition
Balanced asset mix between current and non-current assets, typical of many stable businesses.
Tevogen Bio Holdings Inc. Street Expectations Map
No Target Data
No analyst price targets available for tvgn.
Tevogen Bio Holdings Inc. Insider Positioning
During the last 12 months, insiders have sold $1.77M worth of TVGN shares, with no buying activity reported.
3 Months
0
0.00
0
0.00
+0
+$0
3-6 Months
0
0.00
0
0.00
+0
+$0
6-9 Months
0
0.00
0
0.00
+0
+$0
9-12 Months
0
0.00
1.4M
1.77M
-1.8M
-$1.77M
Top Buyers
No buying activity
Top Sellers
Saadi Ryan H.
Director, 10 Percent Owner, Officer: Chief Executive Officer
$1.77M
Insider Activity Analysis
Net Insider Sentiment
Strong bearish signal with $1.77M net selling. Heavy insider selling may indicate concerns about valuation or near-term prospects.
Buy/Sell Ratio
Very poor ratio. Heavy selling with minimal buying suggests insiders may be concerned about valuation or outlook.
Insider Participation
1 insider sellers vs. 0 buyers. Widespread selling across multiple insiders may signal concerns.
No Dividend Yield Data
TVGN has not reported any dividend yield values in the available annual periods.
tvgn Dividend History
Learning Layer
Related Guides
Build conviction on TVGN by pairing this stock hub with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.